Keywords: Nanocarriers; Gemcitabine; Pancreatic ductal adenocarcinoma; hENT1; RRM2;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: SMA; styrene-maleic acid copolymer; SMALP; SMA lipid particle; MSP; membrane scaffolding protein; GPCR; G protein-coupled receptor; ABC; ATP binding cassette; hENT1; human equilibrative nucleoside transporter 1; CzcD; zinc diffusion facilitator; NMR; nucl
Keywords: MDR; multi-drug resistance; PPI; polypropyleneimine; RBC; red blood cell; WBC; white blood cell; LDH; lactate dehydrogenase; EPR; enhances permeability and retention; FA; folic acid; FR; FA receptor; SMUT; sodium-dependent multi-vitamin transporter; FITC;
Keywords: hENT1; human equilibrative nucleoside transporter-1; NBMPR; S-(4-Nitrobenzyl)-6-thioinosine; dpm; disintegrations per minute; SMALPs; styrene maleic acid copolymer lipid particles.; Membrane proteins; Lipid; Model membrane; Nucleoside transporter, SMALPs;
Keywords: Resectable pancreatic cancer; Adjuvant therapy; Neoadjuvant therapy; Predictive biomarkers; hENT1;
The 4-N-acyl and 4-N-alkyl gemcitabine analogues with silicon-fluoride-acceptor: Application to 18F-Radiolabeling
Keywords: dFdC; 2â²,2â²-difluoro-2â²-deoxycytidine (Gemcitabine); hENT1; human equilibrative nucleoside transport protein 1; dCK; deoxycytidine kinase; dFdU; 2â²,2â²-difluorouridine; CDA; cytidine deaminase; [18F]FAC; 1-(2-deoxy-2-[18F]fluoro-β-d-arabinofuran
Sugar-modified poly(propylene imine) dendrimers as drug delivery agents for cytarabine to overcome drug resistance
Keywords: ALL; acute lymphocytic leukemia; AML; acute myeloid leukemia; Ara-C; cytarabine; Ara-CTP; cytarabine triphosphate; CDD; cytidine deaminase; dCK; deoxycytidine kinase; DP; dipyridamole; FBS; fetal bovine serum; hENT1; human equilibrative nucleoside transpo
Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial
Keywords: Pancreatic cancer; hENT1; Predictive biomarker; Adjuvant therapy; Gemcitabine; CONKO-001;
Thermodynamics and kinetics of inhibitor binding to human equilibrative nucleoside transporter subtype-1
Keywords: NBMPR (PubChem CID: 5129); Dilazep (PubChem CID: 29976); Dipyridamole (PubChem CID: 3108); Adenosine (PubChem CID: 60961); hENT1; human equilibrative nucleoside transporter-1; NBMPR; nitrobenzylmercaptopurine ribonucleoside; ITC; isothermal titration calo
Dilazep analogues for the study of equilibrative nucleoside transporters 1 and 2 (ENT1 and ENT2)
Keywords: Equilibrative nucleoside transporters (ENTs); hENT1; hENT2; rENT2; Dilazep;
Effect of hENT1 polymorphism G-706C on clinical outcomes of gemcitabine-containing chemotherapy for Chinese non-small-cell lung cancer patients
Keywords: hENT1; Polymorphism; Chemotherapy response; Non-small-cell lung cancer;
A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression
Keywords: Gemcitabine-refractory; Pancreas adenocarcinoma; CO-1.01; hENT1; Biomarker; Disease-control rate;
Human equilibrative nucleoside transporter 1 (hENT1): Do we really have a new predictive biomarker of chemotherapy outcome in pancreatic cancer patients?
Keywords: Pancreatic cancer; Membrane transport protein; SLC29A1; hENT1; Gemcitabine;
Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma
Keywords: Cholangiocarcinoma; Gemcitabine; hENT1;
Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma
Keywords: Nucleoside Transporters; Drug Metabolism; Pancreatic Cancer; Biomarker; CI; confidence interval; dCK; deoxycytidine kinase; hENT1; human equilibrative nucleoside transporter 1; HR; hazard ratio; OS; overall survival; PDAC; pancreatic ductal adenocarcinoma
Optimizing Pemetrexed-Gemcitabine Combination in Patients with Advanced Non-small Cell Lung Cancer: A Pharmacogenetic Approach
Keywords: dCK; hENT1; Gene expression; Pemetrexed; Gemcitabine
Research reportBehavioral effects of elevated expression of human equilibrative nucleoside transporter 1 in mice
Keywords: PCR; polymerase chain reaction; hENT1; human equilibrative nucleoside transporter 1; mAK; mouse adenosine kinase; TAE; Tris acetate-EDTA; DMSO; dimethylsulfoxide; dNTPs; deoxynucleoside triphosphates; RT; reverse transcription; DTT; dithiothreitol; [3H]
Biomarkers of Pancreatic Cancer
Keywords: CA19-9; CEA; DUPAN-2; S100P; hENT1; MicroRNA;
The life cycle of human equilibrative nucleoside transporter 1: From ER export to degradation
Keywords: Nucleoside transporter; hENT1; Trafficking; Internalization; Recycling; Degradation
Predicting gemcitabine transport and toxicity in human pancreatic cancer cell lines with the positron emission tomography tracer 3′-deoxy-3′-fluorothymidine
Keywords: Gemcitabine; 3′-Deoxy-3′-fluorothymidine; hENT1; Nucleoside transporters; Predicting toxicity
Characterization of mammalian equilibrative nucleoside transporters (ENTs) by mass spectrometry
Keywords: Nucleoside transporters; hENT1; mENT1; FLAG-affinity; MALDI-TOF; Tandem MS; Regulation
Gene Expression Levels as Predictive Markers of Outcome in Pancreatic Cancer after Gemcitabine-Based Adjuvant Chemotherapy
Keywords: 5â²-NT; 5â²-nucleotidase; AC; adjuvant chemotherapy; CDA; cytidine deaminase; dCK; deoxycytidine kinase; DFS; disease-free survival; EUS-FNA; endoscopic ultrasound-guided fine needle aspiration; FFPE; formalin-fixed paraffin-embedded; hENT1; human equil
CoMFA and CoMSIA 3D-QSAR studies on S6-(4-nitrobenzyl)mercaptopurine riboside (NBMPR) analogs as inhibitors of human equilibrative nucleoside transporter 1 (hENT1)
Keywords: Equilibrative nucleoside transporter; hENT1; Inhibitor; 3D-QSAR; CoMFA; CoMSIA; Cross validation; NBMPR analogs
Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5â²-nucleotidase II expression ratio in primary acute myeloid leukemia cells
Keywords: ara-C; cytarabine or 1-β-d-arabinofuranosylcytosine; ara-CTP; cytarabine triphosphate or 1-β-d-arabinofuranosylcytosine triphosphate; AML; acute myeloid leukemia; hENT1; human equilibrative nucleoside transporter 1; IC50; 50% growth-inhibitory concentra
Altered gene transcription profiles in fibroblasts harboring either TK2 or DGUOK mutations indicate compensatory mechanisms
Keywords: Fibroblasts; hENT1; mtDNA depletion; Mitochondrial dNTP pools; TK2
Modulation of the human equilibrative nucleoside transporter1 (hENT1) activity by IL-4 and PMA in B cells from chronic lymphocytic leukemia
Keywords: hENT1; IL-4; Chronic lymphocytic leukaemia; PKC; Fludarabine; Nucleoside analogs;
The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer
Keywords: hENT1; Immunohistochemistry; Gemcitabine; NSCLC
Human equilibrative nucleoside transporter-1 (hENT1) is required for the transcriptomic response of the nucleoside-derived drug 5′-DFUR in breast cancer MCF7 cells
Keywords: hENT1; 5′-DFUR; Nucleoside transporter; cDNA microarray; Breast cancer